Faster Launch, Increased Adoption, Higher Revenue, and a Playbook for Commercial Success. Read the white paper.
Download Now
Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • Prognos Factor®
    • Marketplace
      • Explore & Buy Data
      • Become a Data Provider
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey Software
      • Physician Segmentation
      • Outcomes Insights
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
  • Company
    • Careers
    • News
    • Insights
    • Resources
  • Contact Us
Home Insights 3 reasons it’s time to shift the paradigm for real world data in pharma

3 reasons it’s time to shift the paradigm for real world data in pharma

  • March 3, 2022
  • Posted in Marketplace
real world data in pharma

Patient-level, real-world data (RWD) in pharma has been used for years to inform drug development and other healthcare-related decision making. The world of RWD is set to explode with expanding data sets and an increasing variety of data sources, including:

  • digitized medical records,
  • lab results and documentation, 
  • claims and billing transactions, 
  • product and disease registries, 
  • device-generated patient data, and more. 

This data will become an even more important factor in generating actionable insights and improving patient outcomes. However, traditional methods of acquiring and applying this data for pharmaceutical product launch and commercialization may be ill-equipped to produce timely and cost-effective results.

A recent survey of pharmaceutical leaders by Reuters Events reinforces this assessment. 

Feedback from the survey shows an existing landscape where: 

  • 60% of pharma RWD budgets are allocated to large data aggregators or direct purchases — a formula already fraught with challenges including expense, source management issues, and data integration complexities. 
  • As such, 68% of survey respondents already believe the way pharmaceutical companies currently purchase patient-level data is ripe for disruption — a sentiment that will only continue to grow as data sets continue to expand. 

3 reasons why the existing paradigm for real world data in pharma needs to change to accommodate data growth:

  1. More sources require simplified management 

Managing multiple data sources and vendors is already a challenge cited by pharmaceutical leaders in the Reuters survey. In fact, 22% of respondents ranked it as the top challenge, referring to the process as time consuming and resource sapping. The expansion of more diverse data sources will only exacerbate this issue unless new methods are employed to consolidate and harness data. For example, a digital marketplace that consolidates health data from multiple sources can allow pharmaceutical companies to quickly query and isolate desired data sets without the lengthy manual processes typically administered by data aggregators.  

  1. Data normalization and integration must improve

Other top RWD process challenges identified through the Reuters survey include data harmonization (37%) and linkability (27%). Under-developed or non-existent industry standards surrounding patient-level health data can make normalizing assets from multiple sources a time-consuming and painstaking task. Similarly, integrating data from different sources — particularly marrying newly acquired data with existing lists — can be a delicate process requiring in-house technical and compliance expertise as well as outside expert determination. Leveraging a technology platform that does this heavy lifting for pharmaceutical companies can provide cost and time savings that provide a real competitive advantage while ensuring ongoing compliance.

  1. Data must deliver faster insights

There was clear consensus from the pharmaceutical leaders surveyed that RWD processes needed to improve and the enhancement most would like to see is faster speed to insight from acquired data. 67% of respondents indicated this as a top priority for improving the way they manage, store, and obtain insights from RWD. Again, digital online marketplaces can help streamline data access, analysis, and application, expediting several steps in traditional RWD processes and enabling much faster data insights.

See how Prognos Marketplace can shift the RWD paradigm and deliver faster speed to insight for your life science organization. Schedule a customized demo today.

« AI-driven risk prediction: A powerful underwriting tool in an era of high inflation
How to use RWD for provider engagement: 3 pharma best practices »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Marketplace
  • Omnichannel Marketing
  • Patient Journey
  • Physician Segmentation
  • Prog Spotlight
  • RWD
  • Technology
  • Underwriting

Archives

Latest Tweets

Prognos HealthFollow

Query billions of fully-integrated lab & health records on more than 325M de-identified patients to answer key healthcare questions in minutes on prognosFACTOR.

Prognos Health
prognosAIPrognos Health@prognosAI·
12 Apr

In our recent panel discussion “How to determine your next best action for every HCP engagement”, leaders from Novartis, GSK, and Takeda Oncology discussed their #RWD strategies to commercialize drug therapies. 3 important best practices were revealed. https://prognoshealth.com/blog/provider-engagement/?utm_source=twitter&utm_medium=social&utm_campaign=provider_engagement_blog

Reply on Twitter 1513876896056057856Retweet on Twitter 1513876896056057856Like on Twitter 1513876896056057856Twitter 1513876896056057856
prognosAIPrognos Health@prognosAI·
7 Apr

68% of #pharma leaders believe the way #lifescience companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help address them.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=rwd_paradigm_shift_blog

#RealWorldData

Reply on Twitter 1512114401360461827Retweet on Twitter 15121144013604618271Like on Twitter 1512114401360461827Twitter 1512114401360461827
prognosAIPrognos Health@prognosAI·
5 Apr

Therapy-related #RWD insights and learnings for a new brand launch can take 12-18 months. One leading #pharma company cut this time in half. Find out how.
https://prognoshealth.com/resource/rwd-analysis/?utm_source=twitter&utm_medium=social&utm_campaign=oncology_case_study

#Omnichannel #Oncology #Pharmaceutical #TherapyLaunch #RealWorldData

Reply on Twitter 1511355425660325897Retweet on Twitter 15113554256603258971Like on Twitter 15113554256603258971Twitter 1511355425660325897
prognosAIPrognos Health@prognosAI·
3 Mar

In a recent survey of #pharma leaders by Reuters, 68% of respondents believe the way #LifeSciences companies currently purchase patient-level data is ripe for disruption.

Find out what challenges dominate current #RWD efforts and how technology can help.

https://prognoshealth.com/blog/real-world-data-pharma-paradigm-shift/?utm_source=twitter&utm_medium=social&utm_campaign=real_world_data_in_pharma_paradigm_shift

Reply on Twitter 1499488030222168066Retweet on Twitter 14994880302221680661Like on Twitter 1499488030222168066Twitter 1499488030222168066
prognosAIPrognos Health@prognosAI·
1 Mar

Dr. Steven Zatz Joins Prognos Health Board of Directors

"Steve’s vision and leadership helped build WebMD into an iconic healthcare brand," says @sundeepbhan1.

https://prognoshealth.com/about-us/news/press-release/dr-steven-zatz-joins-prognos-health-board-of-directors/?utm_source=twitter&utm_medium=social&utm_campaign=dr_zatz_joins_board

Reply on Twitter 1498679196536737795Retweet on Twitter 14986791965367377951Like on Twitter 14986791965367377951Twitter 1498679196536737795
Load More...
  • Prognos Factor®
    • Prognos Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2022. All Rights Reserved.

Get Answers Faster

Watch your questions answered with unparalleled speed. De-identified record level patient data already integrated & easily linked to other sources. Prognos puts you in control.

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.